Pressing Pause on Psychedelic Cash

Analysing the Challenges in Psychedelic Drug Development Through Investment Trends

Adrienne Rivlin

Read more

Related Insights

Executive Insights

Life Sciences & Pharma

Is Biopharma Doing Enough to Advance Novel Targets?

May 15, 2025

Executive Insights

Life Sciences & Pharma

Quantum Computing in Biopharma: Future Prospects and Strategic Insights

May 1, 2025

Life Sciences & Pharma

Unlocking the Potential of Next-Generation PROTACs: A Strategic Roadmap for R&D Investment

March 7, 2025

Our client engaged L.E.K. Consulting to develop a market overview across multiple key therapeutic areas (e.g., oncology, immunology, neuroscience) and…

Life Sciences & Pharma

Clinical Trial Design Strategies To Address Methodological Challenges in Psychedelics

November 15, 2024

Biotech and Pharmaceuticals

Supporting an Emerging Biopharma To Build Out AI With Confidence

October 22, 2024

Executive Insights

Life Sciences & Pharma

Oncology BD&L: Winning in an Increasingly Competitive Environment

September 12, 2024